Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
It is to start participating in a Medicare discount program for such medications, among other measures. This will help make it the go-to pharmacy for many users of weight-loss drugs.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
New $50 monthly copay for eligible Medicare patients, one-on-one pharmacist guidance, and over-the-counter products to help manage common side effects available to support patients MinuteClinic® expands virtual care with new weight management offering and $49 visits WOONSOCKET, R.I., June 22, 2026 /PRNewswire/ -- As demand for GLP-1 medications continues to increase across the U.S., CVS Health® (NYSE: CVS) today announced a comprehensive approach to GLP-1 support spanning its more than 9,000 CVS Pharmacy® locations and MinuteClinic®, available virtually in nearly all states.
Does CVS Health (CVS) have what it takes to be a top stock pick for momentum investors? Let's find out.
CVS Health's financial results are improving due to several initiatives. These efforts could continue to pay off in the short run.
Earlier this month, Mizuho's Ann Hynes raised her price target to $115 per share. Following the latest rally, this implies potential upside of around 13%.
STNE, USNA, STRA, NEXA and CVS passed a low price-to-book screen, combining discounted valuations with projected long-term EPS growth.
CVS Health (CVS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
CVS Health (CVS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.